160 related articles for article (PubMed ID: 35249252)
1. Cemiplimab and ruxolitinib in concomitant cutaneous squamous cell carcinoma and myelofibrosis.
Di Raimondo C; Rao L; Lozzi F; Lombardo P; Silvaggio D; Vellucci L; Tofani L; Campione E; Bianchi L
Dermatol Ther; 2022 May; 35(5):e15421. PubMed ID: 35249252
[No Abstract] [Full Text] [Related]
2. Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.
Di Prima A; Botticelli A; Scalzulli E; Colafigli G; Pepe S; Lisi C; Marchetti P; Martelli M; Foà R; Breccia M
Ann Hematol; 2021 Aug; 100(8):2117-2119. PubMed ID: 32856142
[No Abstract] [Full Text] [Related]
3. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F
J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175
[No Abstract] [Full Text] [Related]
4. Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma.
Hanania HL; Lewis DJ
Expert Rev Anticancer Ther; 2022 Feb; 22(2):237-238. PubMed ID: 34918605
[No Abstract] [Full Text] [Related]
5. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant cemiplimab induces durable complete response in locally advanced cutaneous squamous cell carcinoma.
Geidel G; Adam L; Rünger A; Menz A; Kött J; Haalck T; Gebhardt C
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1414-e1416. PubMed ID: 37458533
[No Abstract] [Full Text] [Related]
7. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case.
Ghidini A; Santangelo D; Vaccaro G; Chillura M; Petrelli F
Oral Oncol; 2022 May; 128():105847. PubMed ID: 35367788
[TBL] [Abstract][Full Text] [Related]
8. Safety of cemiplimab for advanced cutaneous squamous cell carcinoma in a patient with p-ANCA-associated vasculitis.
Pham JP; Sivasubramaniam V; Gallagher R; Forstner D; Wong M; Liu J
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e363-e365. PubMed ID: 36226470
[No Abstract] [Full Text] [Related]
9. RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma.
Morgado-Carrasco D; Bosch-Amate X; Fustà-Novell X; Giavedoni P
Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):161-163. PubMed ID: 31874704
[No Abstract] [Full Text] [Related]
10. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
[TBL] [Abstract][Full Text] [Related]
11. Unresectable auricular squamous cell carcinoma with locoregional metastasis: use of cemiplimab in an immunosuppressed patient.
França TF; Gontijo JRV; Junior EFV; Lima EM
An Bras Dermatol; 2024; 99(1):158-160. PubMed ID: 37652819
[No Abstract] [Full Text] [Related]
12. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Keeping S; Xu Y; Chen CI; Cope S; Mojebi A; Kuznik A; Konidaris G; Ayers D; Sasane M; Allen R; Huynh TM; Popoff E; Freeman M; Andria ML; Fury MG; Singh K; Stockfleth E; Challapalli A; Schmults CD
Future Oncol; 2021 Feb; 17(5):611-627. PubMed ID: 33052055
[No Abstract] [Full Text] [Related]
13. Cemiplimab in advanced cutaneous squamous cell carcinoma.
Naik PP
Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
[TBL] [Abstract][Full Text] [Related]
14. Dichotomic response patterns to PD-1 blockade with cemiplimab in a patient with multiple squamous cell carcinomas.
Bazzacco G; Zelin E; Toffoli L; Conforti C; di Meo N; Fedele D; Zalaudek I
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e547-e549. PubMed ID: 36305888
[No Abstract] [Full Text] [Related]
15. Maintenance of clinical response after short treatment with cemiplimab for advanced squamous cell carcinoma.
Conforti C; Toffoli L; Agozzino M; Fedele D; Moroso S; di Meo N; Zalaudek I
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e443-e445. PubMed ID: 35037322
[No Abstract] [Full Text] [Related]
16. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib: a new first-line strategy in autoimmune myelofibrosis treatment.
Penna D; Tieghi A; Valli R; Merli F
Leuk Lymphoma; 2023 Oct; 64(10):1723-1726. PubMed ID: 37440354
[No Abstract] [Full Text] [Related]
18. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
Actas Dermosifiliogr; 2022 Jun; 113(6):T610-T615. PubMed ID: 35525283
[TBL] [Abstract][Full Text] [Related]
19. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
Actas Dermosifiliogr; 2022 Jun; 113(6):610-615. PubMed ID: 35431057
[TBL] [Abstract][Full Text] [Related]
20. Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia.
Pope V; Hsia CC
Ann Hematol; 2024 Feb; 103(2):677-679. PubMed ID: 37930364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
